A growing number of families choose to bank their babies' umbilical cord blood as a potential cure for dozens of cancers, blood disorders, immune and genetic diseases. Stem cell research is yielding new disease treatments all the time.

The stem cells within cord blood are genetically unique to each child and make them a perfect match for disease treatment. Today, doctors are turning increasingly to cord blood stem cells as a life-saving alternative to bone marrow transplants.

In the near future, stem cells may prove effective in the treatment of an even more diverse group of illnesses and injuries, including spinal cord injuries, stroke, Parkinson's, Alzheimer's, heart disease, diabetes and HIV.

One of the most important factors to consider in any cord blood bank program is its transplant success rate.

StemCyte Family--through our parent company StemCyte--has more experience than any other private cord blood bank for providing transplant quality stem cells. StemCyte cord blood units have contributed to over 1068 transplants by medical centers around the world. And StemCyte, Inc. has banked cord blood units from over 25,000 babies.

• We use a proprietary processing method, monitored by more than 400 quality-based standard operating procedures, that allows over 90% of collected nucleated cells to be retained.
• We have an unparalleled track record, including extensive success in transplants to non-relative children and adults (including a 220 pound adult) – the most common and most difficult kind of transplant.
• We have a commitment to charge a fair price that enables more parents to consider this important medical choice.
• We use the facilities and processes of StemCyte, which has earned the highest industry accreditations—including a perfect accreditation score from the American Association of Blood Banks.